Domperidone: 3 agencies, 2008–2018
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) has been harder on domperidone than on its own caseload: it refused 6 of 18 decisive submissions here (33%), against a base rate of 11% across everything it has assessed.
Assessment has run over 10.1 years, from 8 May 2008 at PHARMAC (New Zealand) to 13 Jun 2018 at HAS (France).
TLV (Sweden) changed its position: not recommended on 7 Jun 2012, restricted by 23 Mar 2018, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), SMC (Scotland) and AWMSG (Wales) among them — hold no record for domperidone at all.
Nothing has been added since 2018; on this evidence the file is dormant.
PHARMAC (New Zealand) was first to assess domperidone, on 8 May 2008; TLV (Sweden) did not open a file until 7 Jun 2012 — a wide spread of 4.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 11 of 22 dated records fall in 2016 alone.
2 of the 3 agencies here assessed domperidone more than once, HAS (France) most often at 18 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed domperidone.
The full ledger for domperidone reads 13 recommended, 7 not recommended and 2 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 13 Jun 2018 | Listing (Transparency Committee) | SMR low · ASMR V | source |
| TLV (Sweden) | 23 Mar 2018 | Domperidon Ebb ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| HAS (France) | 8 Mar 2017 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| HAS (France) | 11 Jan 2017 | Listing (Transparency Committee) | SMR low · ASMR V | source |
| PHARMAC (New Zealand) | 8 May 2008 | removal of Special Authority and fully funding | PTAC advice: Recommended for funding with no priority · decision reached | source |
17 further decisions for domperidone, across 2 agencies, are not shown here. They link to 11 further source documents.
Related molecules
- busulfan — also decided by HAS in 2018Q2
- naloxone / oxycodone — also decided by HAS in 2018Q2
- trabectedin — also decided by HAS in 2018Q2
- cerliponase alfa — also decided by HAS in 2018Q2
- venlafaxine — also decided by HAS in 2018Q2
- ipilimumab — also decided by HAS in 2018Q2
Coverage: 22 decisions for domperidone from 3 agencies, 2008 to 2018. Data to 7 Sep 2026. ATC class A03F — Functional GI disorders. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.